A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths. The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year. [time-brightcove not-tgx=”true”] In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prev
Hence then, the article about a blood test for colon cancer shows promise was published today ( ) and is available onTime ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( A Blood Test for Colon Cancer Shows Promise )